Desmopressin for Bedwetting in Children With SCD

Stopped early · Phase 4

Conditions studied: Nocturnal Enuresis, Anemia, Sickle Cell

In brief

This study assesses if using the medication desmopressin will decrease nightime bedwetting in children with sickle cell disease.

Key facts

Study ID

NCT04420585

Run by

Montefiore Medical Center

People needed

8

Starts

2020-07-07

Expected to finish

2023-06-12

Last updated by the study team

2024-05-07

Who can join

Age: 8 and older, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with Hemoglobin SS, SC, SB0thal or SB+thal
• Patients with at least two episodes of primary nocturnal enuresis per week or four episodes over the two weeks prior to enrollment.
• Patients with secondary enuresis who have been evaluated and cleared by a pediatric urologist as not having other etiologies of enuresis (e.g. overactive detrusor activity, a genitourinary anatomic abnormality)

You may not qualify if…

• Patients with developmental delay or neurologic dysfunction secondary to stroke.
• Patients with hypertension or underlying renal disease.
• Patients with genitourinary anatomic abnormalities. Any prior renal ultrasound showing normal genitourinary anatomy is sufficient to clear a patient for the study.
• Patients with daytime urinary incontinence
• Patients with glucosuria on urinalysis.
• Patients with secondary nocturnal enuresis who have not been evaluated by a pediatric urologist to rule out other etiologies of enuresis.
• Patients who are pregnant.
• Patients receiving another medicine for nocturnal enuresis (e.g. imipramine).

Where it is running

• Children's Hospital at Montefiore — The Bronx, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.